Are You Sick of Hearing About Interest Rates Yet?
Insights - Following the release of minutes from the Fed’s July Open Market Committee (FOMC) meeting on Wednesday, U.S. markets opened lower and continued lower in early … Continue Reading
Read NowInsights
Gilead Beats, Raises, Waylays Growth Naysayers
Insights - Gilead Sciences (GILD) reported a blowout quarter on Tuesday afternoon, topping consensus estimates across the board and possibly stopping the bleeding — at least temporarily — … Continue Reading
Read Now
A Rough Close to the Week for Biotech Stocks
Insights - To say that Biogen (BIIB) disappointed in a big way on Friday would be an understatement. With its second quarter earnings release on Friday morning … Continue Reading
Read Now
Your 30-Second Primer on Biopharma’s Second Quarter Earnings
Insights - Second quarter earnings from the large, publicly traded biopharma and specialty pharma companies begin to trickle out on Thursday, July 23. Below is your cheat sheet … Continue Reading
Read NowIt’s Been a Yawner of a Summer
Insights - The prettiest girl at the ball, Receptos (RCPT), went home with a handsome suitor this week. Celgene (CELG) is paying $7.2 billion, or $232 per … Continue Reading
Read Now
Sleep Easy Healthcare Investors; Receptos has Been Bought
Insights - Healthcare investors can sleep easy tonight with one of 2015’s major unanswered questions now off the table. Celgene (CELG) will buy Receptos (RCPT) for $7.2 billion, or $232 in … Continue Reading
Read Now
Yet Again, This Weekend May Be More Important Than This Week
Insights - Yet another choppy week for investors, and we’re going into another weekend in which decisions overseas will impact U.S. markets first thing on Monday. Greece submitted … Continue Reading
Read Now